VIDEO: Tools to assess treatment benefits in patients with dry AMD ‘inadequate’
CHICAGO —In this video, Karl G. Csaky, MD, PhD, highlights discussions from the AAO meeting on the adequacy of tools used to assess the effectiveness of treatments for dry age-related macular degeneration.
While there are therapies being developed that may have better neuroprotective elements and functional benefits, the tools that are used to assess the effects of these treatments are inadequate, according to Csaky, chief executive and medical officer of the Retina Foundation of the Southwest in Dallas.
“We don’t really have ease-of-use tools to really understand how best to follow these patients as well as to demonstrate to the patients and their relatives and their family members that in fact there is benefit at some point along the way,” he said.
Collapse
Healio Interviews
Read more about